GVR Report cover Antimicrobial Resistance Diagnostics Market Size, Share & Trends Report

Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report By Technology (Microbiology Culture, Immunoassay, PCR, NGS), By End-user, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453390
  • Number of Pages: 0
  • Format: Electronic (PDF)

The growth of the antimicrobial resistance diagnostics market is attributed to the increased risk of developing drug-resistant bacterial infections, the introduction of novel technologies, and increasing government initiatives to diagnose & reduce AMR infections. To address the global health challenge of AMR, government bodies such as the U.S. FDA support the development of next-generation sequencing-based diagnostic tests to identify the right pathogen to help healthcare providers to treat infections more accurately.

Increasing adoption of point of care and rapid testing for drug-resistant microbial infections is expected to fuel the market growth in the forecast period. PCR technology-based POC tests are expected to control the progression of hospital-acquired infections (HAIs) in healthcare facilities. Moreover, key market players such as Abbott, F. Hoffmann-La Roche Ltd, and others have a strong product portfolio of rapid diagnostic tests for multiple drug-resistant infections. Moreover, increasing involvement of government and non-government bodies such as the AMR Industry Alliance is helping to build strategies to support diagnostic development to reduce antimicrobial resistance.

The AMR diagnostics market is segmented based on technology, pathogen, and end-user. Among the technology segment, the polymerase chain reaction segment held the largest share in 2021 and is expected to maintain its dominance through the forecast period. High penetration of PCR technology and advancements in the technology has increased the segment share. Moreover, the high adoption rate of PCR tests for HAIs such as c. difficile and MRSA is further driving segment growth. However, the rapid & point of care segment is anticipated to grow at the fastest rate in the forecast period.

North America is the largest market for antimicrobial resistance diagnostics. The high risk of developing AMR infections, developed healthcare infrastructure, favorable healthcare policies, and presence of key market players in the region have increased the market share. According to an article published by CDC in August 2022, in the U.S., around 2.8 million people are diagnosed with antibiotic-resistant infections each year. MRSA and c.difficile are major prevalent infections reported in the U.S. However, the Asia Pacific is expected to grow at the fastest rate during the forecast period. The growth of the region can be attributed to the increasing adoption of novel diagnostic techniques, improving healthcare policies, and increasing awareness among people is expected to fuel the segment growth in the region.

Antimicrobial Resistance Diagnostics Market Segmentation

Segments

Details

Technology

Microbiology Culture, Immunoassay, PCR, NGS, Mass Spectrometry, Rapid & Point of Care

Others

Pathogen

Drug Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Campylobacter (DRC), Clostridium Difficile (CD), Methicillin Resistant Staphylococcus Aureus (MRSA), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRNTS), Others

End-User

Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others

Region

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

Key players operating in the antimicrobial resistance diagnostics market include F. Hoffmann-La Roche, Ltd., Abbott, BD, Danaher, and Accelerate Diagnostics, Inc. Companies are adopting market strategies such as collaboration to increase their presence across the globe. For instance, in August 2022 , BD and Accelerate Diagnostics collaborated to address the threat of antimicrobial resistance. According to the deal, BD will offer Accelerate's rapid testing solution for antibiotic resistance to its large customer base of clinical microbiology systems.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.